N6 - methyladenosine RNA modification in acute coronary syndrome

The main aim of the MAACS project is to explore if specific changes in epitranscriptomic landscape of peripheral blood mononuclear cells (PBMCs), particularly N6-methyladenosine (m6A) RNA modification, could be used as a biomarker for acute coronary syndrome (ACS) differential diagnosis and prediction of future adverse outcomes.

This project will be the first to (1) identify ACS-specific m6A biosignatures in PBMCs using direct RNA Nanopore sequencing, (2) quantify total m6A RNA modifications in PBMCs of ACS and stable angina patients using LC/MS, (3) assess the clinical utility of total m6A RNA modification in PBMCs, and (4) perform an in vitro functional analysis of ACS-specific m6A modifications.

The realization of set objectives will reveal novel mechanisms implicated in the aggravation of ACS that could lead to the development of novel tools for personalized prevention, diagnosis, and treatment.

In order to utilize the power of the integrative and multidisciplinary approach, this project will establish collaboration between Dr.

Miron Sopic (MSCA PF applicant) and top-tier institutions: CardioVascular Research Unit-Luxembourg Institute of Health (beneficiary) led by Dr.

Yvan Devaux (The project’s supervisor), McGill University in Quebec (associated partner for secondment), and University of Luxembourg (associated partner).

Working in the international environment with eminent experts and a productive team of researchers and using state-of-the-art infrastructure and techniques will secure the applicant to become an internationally recognized expert in the epitranscriptomic field and an independent researcher with strong credibility competent to establish and lead his research group.

MAACS contributes to sustainable development by complying with several objectives: good health and well-being, quality education, gender equality in research, reduced inequalities, and partnership for the goals.